Steve is the Chief Medical Officer of Allievex Corporation, a clinical-stage pharmaceutical company developing therapies for Sanfilippo syndrome type B and other pediatric neurodegenerative disorders. He is also the acting Chief Medical Officer of Grace Sciences LLC, a biotechnology company whose aim is to develop a gene therapy for NGly1 deficiency, another devastating neurological disease of childhood. Steve is a board-certified child neurologist and clinical development scientist with experience in rare disease therapeutic development and specific expertise in enzyme replacement and gene therapy. He previously worked in clinical development at BioMarin Pharmaceutical and has served on the Pediatrics and Child Neurology faculty at three world-renowned children’s hospitals. Steve was an NIH- and privately-funded basic science primary investigator who is internationally recognized for research in neural development. He is a recipient of the Child Neurology Society Philip R. Dodge Young Investigator Award for outstanding early career research.